Precision therapy for Respiratory Long COVID

Long COVID affects hundreds of millions worldwide; more than a third have persistent respiratory symptoms. No validated biomarkers or approved therapies exist, leaving most patients with Respiratory Long COVID undiagnosed and untreated. Backed by three years of research at Yale, we have identified a treatable disease mechanism, a quantitative biomarker for this trait, and targeted therapies with promising early data in patients. Partner with us to translate these discoveries rapidly into clinical practice.